Patents by Inventor Clyde W. Hodge

Clyde W. Hodge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Protein kinase C epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse
    Patent number: 7534859
    Abstract: The present invention is directed to the production of PKC isozyme ? (PKC?)-deficient cells and non-human animals. The present invention is further directed to the identification of PKC? as a target for drugs that reduce anxiety. According to the present invention, PKC?-inhibiting compounds act in synergy with drugs acting at the GABAA receptor. The present invention is also directed to the use of modulators of PKC? to modulate alcohol consumption, self-administration of other drugs of abuse, and the effects of alcohol consumption as well as the use of inhibitors of PKC?, either alone or in conjunction with allosteric agonists of GABAA receptors, to treat conditions, such as addiction, withdrawal syndrome, skeletal muscle spasms, convulsive seizures, and epilepsy, that are amenable to treatment by allosteric agonists of GABAA receptors.
    Type: Grant
    Filed: August 8, 2006
    Date of Patent: May 19, 2009
    Assignee: The Regents of the University of California
    Inventors: Robert O Messing, Clyde W Hodge
  • Protein kinase C epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse
    Publication number: 20040191898
    Abstract: The present invention is directed to the production of PKC isozyme &egr; (PKC&egr;)-deficient cells and non-human animals. The present invention is further directed to the identification of PKC&egr; as a target for drugs that reduce anxiety. According to the present invention, PKC&egr;-inhibiting compounds act in synergy with drugs acting at the GABAA receptor. The present invention is also directed to the use of modulators of PKC&egr; to modulate alcohol consumption, self-administration of other drugs of abuse, and the effects of alcohol consumption as well as the use of inhibitors of PKC&egr;, either alone or in conjunction with allosteric agonists of GABAA receptors, to treat conditions, such as addiction, withdrawal syndrome, skeletal muscle spasms, convulsive seizures, and epilepsy, that are amenable to treatment by allosteric agonists of GABAA receptors.
    Type: Application
    Filed: December 23, 2003
    Publication date: September 30, 2004
    Applicant: The Regents of the University of California
    Inventors: Robert O. Messing, Clyde W. Hodge
  • Protein kinase C epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse
    Patent number: 6717030
    Abstract: The present invention is directed to the production of PKC isozyme &egr; (PKC&egr;)-deficient cells and non-human animals. The present invention is further directed to the identification of PKC&egr; as a target for drugs that reduce anxiety. According to the present invention, PKC&egr;-inhibiting compounds act in synergy with drugs acting at the GABAA receptor. The present invention is also directed to the use of modulators of PKC&egr; to modulate alcohol consumption, self-administration of other drugs of abuse, and the effects of alcohol consumption as well as the use of inhibitors of PKC&egr;, either alone or in conjunction with allosteric agonists of GABAA receptors, to treat conditions, such as addiction, withdrawal syndrome, skeletal muscle spasms, convulsive seizures, and epilepsy, that are amenable to treatment by allosteric agonists of GABAA receptors.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: April 6, 2004
    Assignee: The Regents of the University of California
    Inventors: Robert O. Messing, Clyde W. Hodge
  • Use of neuropeptide-y antagonists in treatment of alcoholism
    Publication number: 20040029953
    Abstract: The present invention provides a method of treating of alcoholism and alcohol abuse in a mammal comprising administering a therapeutically effective amount of an NPY receptor antagonist. The present invention is also directed to pharmaceutical compositions containing the same.
    Type: Application
    Filed: September 19, 2003
    Publication date: February 12, 2004
    Inventor: Clyde W. Hodge
  • PROTEIN KINASE C EPSILON AS MODULATOR OF ANXIETY, ALCOHOL CONSUMPTION AND SELF-ADMINISTRATION OF DRUGS OF ABUSE
    Publication number: 20020124272
    Abstract: The present invention is directed to the production of PKC isozyme &egr; (PKC&egr;)-deficient cells and non-human animals. The present invention is further directed to the identification of PKC&egr; as a target for drugs that reduce anxiety. According to the present invention, PKC&egr;-inhibiting compounds act in synergy with drugs acting at the GABAA receptor. The present invention is also directed to the use of modulators of PKC&egr; to modulate alcohol consumption, self-administration of other drugs of abuse, and the effects of alcohol consumption as well as the use of inhibitors of PKC&egr;, either alone or in conjunction with allosteric agonists of GABAA receptors, to treat conditions, such as addiction, withdrawal syndrome, skeletal muscle spasms, convulsive seizures, and epilepsy, that are amenable to treatment by allosteric agonists of GABAA receptors.
    Type: Application
    Filed: June 25, 1999
    Publication date: September 5, 2002
    Inventors: ROBERT O. MESSING, CLYDE W. HODGE